Acute and chronic systemic CB1 cannabinoid receptor blockade improves blood pressure regulation and metabolic profile in hypertensive (mRen2)27 rats

Physiological Reports

Volumn 2, Issue 8, 2014, Pages

  Schaich, Chris L ^a   Shaltout, Hossam A ^a   Brosnihan, K Bridget ^a   Howlett, Allyn C ^a   Diz, Debra I ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Baroreflex; Endocannabinoid system; Hypertension; Metabolic syndrome; Reninangiotensin system

Indexed keywords

ANGIOTENSIN; CANNABINOID 1 RECEPTOR; ENDOCANNABINOID; HORMONE; INSULIN; LEPTIN; RENIN; RIMONABANT;

ANIMAL MODEL; ARTICLE; BLOOD PRESSURE REGULATION; BODY MASS; FAT MASS; FOOD INTAKE; HEMODYNAMICS; HYPERTENSION; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; NONHUMAN; OSMOLALITY; PLASMA; RAT; RECEPTOR BLOCKING; SYSTOLIC BLOOD PRESSURE; URINE; VAGUS TONE; WEIGHT GAIN;

EID: 85002595440     PISSN: None     EISSN: 2051817X     Source Type: Journal    
DOI: 10.14814/phy2.12108     Document Type: Article

References (60)

1. Arita, Y., S. Kihara, N. Ouchi, M. Takahashi, K. Maeda, J. Miyagawa, et al. 1999. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun. 257: 79-83.
2. Arnold, A. C., H. A. Shaltout, P. E. Gallagher, and D. I. Diz. 2009. Leptin impairs cardiovagal baroreflex function at the level of the solitary tract nucleus. Hypertension 54: 1001-1008.
3. Bader, M., Y. Zhao, M. Sander, M. A. Lee, J. Bachmann, M. Bohm, et al. 1992. Role of tissue renin in the pathophysiology of hypertension in TGR(mREN2)27 rats. Hypertension 19: 681-686.
4. Batkai, S., P. Pacher, D. Osei-Hyiaman, S. Radaeva, J. Liu, J. Harvey-White, et al. 2004. Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation 110: 1996-2002.
5. Bellocchio, L., E. Soria-Gomez, C. Quarta, M. Metna-Laurent, P. Cardinal, E. Binder, et al. 2013. Activation of the sympathetic nervous system mediates hypophagic and anxiety-like effects of CB(1) receptor blockade. Proc. Natl Acad. Sci. USA 110: 4786-4791.
6. Bramlage, P., E. Schonrock, and P. Odoj. 2008. Metabolic effects of an AT1-receptor blockade combined with HCTZ in cardiac risk patients: a non interventional study in primary care. BMC Cardiovasc. Disord. 8: 30.
7. Chappell, M. C., P. E. Gallagher, D. B. Averill, C. M. Ferrario, and K. B. Brosnihan. 2003. Estrogen or the AT1 antagonist olmesartan reverses the development of profound hypertension in the congenic mRen2, Lewis rat. Hypertension 42: 781-786.
8. Cinar, R., G. Godlewski, J. Liu, J. Tam, T. Jourdan, B. Mukhopadhyay, et al. 2014. Hepatic cannabinoid-1 receptors mediate diet-induced insulin resistance by increasing de novo synthesis of long-chain ceramides. Hepatology 59: 143-153.
9. Cota, D., G. Marsicano, M. Tschop, Y. Grubler, C. Flachskamm, M. Schubert, et al. 2003. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J. Clin. Invest. 112: 423-431.
10. Despres, J. P., A. Golay, and L. Sjostrom. 2005. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med. 353: 2121-2134.
11. Di Marzo, V., S. K. Goparaju, L. Wang, J. Liu, S. Batkai, Z. Jarai, et al. 2001. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410: 822-825.
12. Diez, J. J., and P. Iglesias. 2003. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur. J. Endocrinol. 148: 293-300.
13. Fisher, J. P., S. Ogoh, C. Junor, A. Khaja, M. Northrup, and P. J. Fadel. 2009. Spontaneous baroreflex measures are unable to detect age-related impairments in cardiac baroreflex function during dynamic exercise in humans. Exp. Physiol. 94: 447-458.
14. Go, A. S., D. Mozaffarian, V. L. Roger, E. J. Benjamin, J. D. Berry, M. J. Blaha, et al. 2014. Heart disease and stroke statistics-2014 update: a report from the american heart association. Circulation 129: e28-e292.
15. Gradin, K., and B. Persson. 1990. Blood pressure and sympathetic activity in spontaneously hypertensive rats during food restriction. J. Neural Transm. Gen. Sect. 79: 183-191.
16. Grassi, G., F. Quarti-Trevano, G. Seravalle, F. Arenare, G. Brambilla, and G. Mancia. 2008. Blood pressure lowering effects of rimonabant in obesity-related hypertension. J. Neuroendocrinol. 20(Suppl. 1): 63-68.
17. Grundy, S. M., J. I. Cleeman, S. R. Daniels, K. A. Donato, R. H. Eckel, B. A. Franklin, et al. 2005. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112: 2735-2752.
18. Gyombolai, P., D. Pap, G. Turu, K. J. Catt, G. Bagdy, and L. Hunyady. 2012. Regulation of endocannabinoid release by G proteins: a paracrine mechanism of G protein-coupled receptor action. Mol. Cell. Endocrinol. 353: 29-36.
19. Herichova, I., and K. Szantoova. 2013. Renin-angiotensin system: upgrade of recent knowledge and perspectives. Endocr. Regul. 47: 39-52.
20. Ho, W. S., and S. M. Gardiner. 2009. Acute hypertension reveals depressor and vasodilator effects of cannabinoids in conscious rats. Br. J. Pharmacol. 156: 94-104.
21. 1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats. Kidney Int. 72: 1345-1357.
22. Kasper, S. O., C. S. Carter, C. M. Ferrario, D. Ganten, L. F. Ferder, W. E. Sonntag, et al. 2005. Growth, metabolism, and blood pressure disturbances during aging in transgenic rats with altered brain renin-angiotensin systems. Physiol. Genomics 23: 311-317.
23. 1 receptor antagonists: new discoveries leading to new perspectives. Acta Physiol. (Oxf) 205: 41-60.
24. Lake, K. D., B. R. Martin, G. Kunos, and K. Varga. 1997. Cardiovascular effects of anandamide in anesthetized and conscious normotensive and hypertensive rats. Hypertension 29: 1204-1210.
25. Lamont, L. S. 1995. Beta-blockers and their effects on protein metabolism and resting energy expenditure. J. Cardiopulm. Rehabil. 15: 183-185.
26. Lindborg, K. A., S. Jacob, and E. J. Henriksen. 2011. Effects of chronic antagonism of endocannabinoid-1 receptors on glucose tolerance and insulin action in skeletal muscles of lean and obese Zucker rats. Cardiorenal Med. 1: 31-44.
27. Maffei, M., J. Halaas, E. Ravussin, R. E. Pratley, G. H. Lee, Y. Zhang, et al. 1995. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat. Med. 1: 1155-1161.
28. McKernan, A. M., and F. R. Calaresu. 1996. Insulin microinjection into the nucleus tractus solitarii of the rat attenuates the baroreceptor reflex. J. Auton. Nerv. Syst. 61: 128-138.
29. 1 antagonist, rimonabant on the blood pressure, and vascular reactivity of obese Zucker rats. Obesity (Silver Spring) 17: 1340-1347.
30. Muller-Fielitz, H., N. Hubel, M. Mildner, F. M. Vogt, J. Barkhausen, and W. Raasch. 2014. Chronic blockade of angiotensin AT1 receptors improves cardinal symptoms of metabolic syndrome in diet-induced obesity in rats. Br. J. Pharmacol. 171: 746-760.
31. Nedvidkova, J., K. Smitka, V. Kopsky, and V. Hainer. 2005. Adiponectin, an adipocyte-derived protein. Physiol. Res. 54: 133-140.
32. Nicholas, S. B. 1999. Lipid disorders in obesity. Curr. Hypertens. Rep. 1: 131-136.
33. Nickenig, G., O. Jung, K. Strehlow, O. Zolk, W. Linz, B. A. Scholkens, et al. 1997. Hypercholesterolemia is associated with enhanced angiotensin AT1-receptor expression. Am. J. Physiol. 272: H2701-H2707.
34. Northcott, C. A., S. Watts, Y. Chen, M. Morris, A. Chen, and J. R. Haywood. 2010. Adenoviral inhibition of AT1a receptors in the paraventricular nucleus inhibits acute increases in mean arterial blood pressure in the rat. Am. J. Physiol. Regul. Integr. Comp. Physiol. 299: R1202-R1211.
35. 1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J. Clin. Invest. 115: 1298-1305.
36. Pakdeechote, P., W. R. Dunn, and V. Ralevic. 2007. Cannabinoids inhibit noradrenergic and purinergic sympathetic cotransmission in the rat isolated mesenteric arterial bed. Br. J. Pharmacol. 152: 725-733.
37. Pavel, J., J. Benicky, Y. Murakami, E. Sanchez-Lemus, and J. M. Saavedra. 2008. Peripherally administered angiotensin II AT1 receptor antagonists are anti-stress compounds in vivo. Ann. N. Y. Acad. Sci. 1148: 360-366.
38. Pertwee, R. G., A. C. Howlett, M. E. Abood, S. P. Alexander, V. Di Marzo, M. R. Elphick, et al. 2010. International union of basic and clinical pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB(1) and CB(2). Pharmacol. Rev. 62: 588-631.
39. Perwitz, N., M. Fasshauer, and J. Klein. 2006. Cannabinoid receptor signaling directly inhibits thermogenesis and alters expression of adiponectin and visfatin. Horm. Metab. Res. 38: 356-358.
40. Poirier, B., J. P. Bidouard, C. Cadrouvele, X. Marniquet, B. Staels, S. E. O’Connor, et al. 2005. The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes. Metab. 7: 65-72.
41. 1 receptor antagonist, in diet-induced obese mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 284: R345-R353.
42. Rozenfeld, R., A. Gupta, K. Gagnidze, M. P. Lim, I. Gomes, D. Lee-Ramos, et al. 2011. AT1R-CB(1)R heteromerization reveals a new mechanism for the pathogenic properties of angiotensin II. EMBO J. 30: 2350-2363.
43. Ruilope, L. M., J. P. Despres, A. Scheen, X. Pi-Sunyer, G. Mancia, A. Zanchetti, et al. 2008. Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results. J. Hypertens. 26: 357-367.
44. 1 cannabinoid receptor tone contributes to impaired baroreflex sensitivity in hypertensive (mRen2)27 transgenic rats. FASEB J. 27: 926.913 (Abstract).
45. Shaltout, H. A., and A. A. Abdel-Rahman. 2005. Mechanism of fatty acids induced suppression of cardiovascular reflexes in rats. J. Pharmacol. Exp. Ther. 314: 1328-1337.
46. Silvestri, C., A. Ligresti, and V. Di Marzo. 2011. Peripheral effects of the endocannabinoid system in energy homeostasis: adipose tissue, liver and skeletal muscle. Rev. Endocr. Metab. Disord. 12: 153-162.
47. Slavic, S., D. Lauer, M. Sommerfeld, U. R. Kemnitz, A. Grzesiak, M. Trappiel, et al. 2013. Cannabinoid receptor 1 inhibition improves cardiac function and remodelling after myocardial infarction and in experimental metabolic syndrome. J. Mol. Med. (Berl) 91: 811-823.
48. Sloniger, J. A., V. Saengsirisuwan, C. J. Diehl, B. B. Dokken, N. Lailerd, A. M. Lemieux, et al. 2005a. Defective insulin signaling in skeletal muscle of the hypertensive TG (mREN2)27 rat. Am. J. Physiol. Endocrinol. Metab. 288: E1074-E1081.
49. Sloniger, J. A., V. Saengsirisuwan, C. J. Diehl, J. S. Kim, and E. J. Henriksen. 2005b. Selective angiotensin II receptor antagonism enhances whole-body insulin sensitivity and muscle glucose transport in hypertensive TG(mREN2)27 rats. Metabolism 54: 1659-1668.
50. 1 cannabinoid receptors. J. Biol. Chem. 287: 31540-31550.
51. Tam, J., G. Godlewski, B. J. Earley, L. Zhou, T. Jourdan, G. Szanda, et al. 2014. Role of adiponectin in the metabolic effects of cannabinoid receptor-1 blockade in mice with diet-induced obesity. Am. J. Physiol. Endocrinol. Metab. 306: E457-E468.
52. 1 receptor inverse agonist, rimonabant, modifies body weight and adiponectin function in diet-induced obese rats as a consequence of reduced food intake. Pharmacol. Biochem. Behav. 84: 353-359.
53. 1 receptor inhibition leads to decreased vascular AT1 receptor expression, inhibition of oxidative stress and improved endothelial function. Basic Res. Cardiol. 105: 465-477.
54. Toblli, J. E., M. C. Munoz, G. Cao, J. Mella, L. Pereyra, and R. Mastai. 2008. ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats. Obesity (Silver Spring) 16: 770-776.
55. 1 cannabinoid receptor by AT1 angiotensin and other Gq/11 protein-coupled receptors. J. Biol. Chem. 284: 16914-16921.
56. Udelsman, R., J. A. Norton, S. E. Jelenich, D. S. Goldstein, W. M. Linehan, D. L. Loriaux, et al. 1987. Responses of the hypothalamic-pituitary-adrenal and renin-angiotensin axes and the sympathetic system during controlled surgical and anesthetic stress. J. Clin. Endocrinol. Metab. 64: 986-994.
57. Van Gaal, L. F., A. M. Rissanen, A. J. Scheen, O. Ziegler, and S. Rossner. 2005. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365: 1389-1397.
58. 1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology 167: 103-111.
59. Wagner, J. A., K. Varga, Z. Jarai, and G. Kunos. 1999. Mesenteric vasodilation mediated by endothelial anandamide receptors. Hypertension 33: 429-434.
60. Wenzel, U. O., R. Benndorf, and S. Lange. 2013. Treatment of arterial hypertension in obese patients. Semin. Nephrol. 33: 66-74.